Nrx Pharmaceuticals Inc NRXP

$2.28 -0.16 (-6.56%)

Valuation

Market cap
106,496,000
Revenue TTM
$1,230,000
Net income TTM
$-28,620,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-2,326.83%
Debt to equity
-2.41

Trading

Volume
604,500
Avg volume
1,102,618
Day's range
$2.25 – $2.44
Shares out
43,646,000
Stochastic %K
43%
Beta
2.11
Analysts
Moderate Buy
Price target
$35.33

Price

Company profile

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinica...

Show more

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Industry
Biotechnology
Sector
Healthcare
Phone
484 254 6134
Website
https://www.nrxpharma.com
Address
1201 N. Market Street, Suite 111, Wilmington, United States

Latest news

Stocktwits

Trending__Now Nov 13, 6:26 AM
$NRXP The shorts could be playing the additional capital spending. IF, $5 per vial, and JJ believes 50% gross profit is acceptable, then we have 5 million vials costing around $3.33 = $16.65 million, plus the additional sales staff and startup expenses, we could be burning up $20 million by December depending on credit terms and sales conditions. I believe JJ mentioned profitability by mid 2027? Slow upward grind unless new institutional buyers are believers. Short shares are only loans. Looking forward to earnings. Hopefully exciting. For us, not the shorts.
1 replies
PSM_EmpowerTrading Nov 13, 5:34 AM
🌅 Watchlist part 2 ✅ $BKHA support in the low 9s; above 10, potential to 11/12 ✅ $VTSI 3.20 support; above 3.65, potential to 3.80/4.50 ✅ $SLND ideal if above 1 🎯 Ideal stop loss: below current support 🚨 Avoid chasing long into strength near resistance ⏳⏳ $NRXP $PMVP still in the swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
0 replies
Trending__Now Nov 13, 12:11 AM
$NRXP End of the day added. LOL, I think it's fairly safe heading into next year potential.
1 replies
PHARMASTOCKONLY Nov 12, 10:44 PM
$NRXP My position is in NRXP, and I don't give a damn
0 replies
flybyme Nov 12, 9:09 PM
$NRXP Provide Corporate Update The Company will host a conference call at 8:00am ET the same day. Bring some top news .
2 replies
flybyme Nov 12, 9:07 PM
$NRXP Good before hours 17 Nov. Stop the shorts over night. Thank you JJ
0 replies
flybyme Nov 12, 9:06 PM
$NRXP https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-inc-nasdaqnrxp-report-third-quarter-2026
0 replies
the_franz Nov 12, 6:24 PM
$NRXP Bye bye CNPV. https://www.reuters.com/world/us-fda-shelves-commissioners-voucher-program-speedy-drug-reviews-sources-say-2026-11-12/
3 replies